Full-Time
Study Participant Call Center Representative
Spanish Bilingual
Posted on 12/12/2025
Celerion
1,001-5,000 employees
Global CRO for early-phase development
Compensation Overview
$17.50/hr
Tempe, AZ, USA
Hybrid
Post-training, role may shift to remote work from the Phoenix, AZ metro area after 90 days.
 Customer Experience & Support (1) |
|---|
- High school diploma or GED
- Minimum 1 year of prior call center experience
- Bilingual Spanish-English fluency is required
- Prior data entry experience
- Must be 18 years of age
- Must demonstrate excellent communication and customer service skills
- Answer inbound calls from members of the public interested in participating in our Phase 1 clinical drug trials
- Screen callers for study eligibility, and then collect and enter personal data for those eligible to participate
- Make outbound calls to schedule appointments, as needed
Celerion is a global contract research organization focused on early-phase drug development. It supports pharmaceutical and biotech clients with trial design, feasibility, project management, clinical and medical monitoring, bioanalytical sciences, and regulatory affairs, all conducted under contract. Its work hinges on metabolite profiling using high-resolution mass spectrometry to inform development decisions. With 40+ years of experience and a global, integrated service network, Celerion aims to help clients bring safe, effective treatments to patients faster by delivering rigorous, timely research.
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
N/A
Headquarters
Lincoln, Nebraska
Founded
2010
Simplify's Take
What believers are saying
- THL Partners' acquisition post-H.I.G. 2022 investments accelerates Celerion's global expansion.
- Labnotes software enhanced May 6, 2025, streamlines bioanalytical data for faster sponsor decisions.
- GLP/GCP molecular testing expansion supports surging cell/gene therapy demand in Lincoln/Zürich.
What critics are saying
- THL Partners cuts costs post-acquisition, eroding Celerion employee retention within 12-24 months.
- WuXi AppTec Belfast expansion captures EU clients with 40% lower HRMS pricing in 6-12 months.
- FDA AI audits expose Labnotes flaws, holding 30% bioanalytical submissions for 6 months.
What makes Celerion unique
- Celerion pioneered VCT biometric fingerprint technology, verifying 50,000 participants over five years.
- Celerion earned first US CRO full AAHRPP accreditation, exceeding federal participant protections.
- Celerion leads early-phase CROs with 650+ beds across North America, Europe, and Asia.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 4%LINCOLN, Neb.; May 6, 2025 (Business Wire) – Celerion, a global leader in early clinical research and bioanalytical services, announced the launch of the latest version of Labnotes, its cutting-edge bioanalytical electronic laboratory notebook software elevating data handling and analysis capabilities for sponsors. The latest system enhancements streamline laboratory documentation and improve operational efficiency for users. The updated platform also offers advanced tools for handling and organizing large datasets, ensuring faster processing of reports and optimized database queries
Celerion launches enhanced version of labnotes bioanalytical data Management software.
Celerion was recognized as a CRO Leader in the quality, capabilities and reliability categories across two groups of respondents (small pharma and combined big and small pharma).
Celerion announced the appointment of Jo Goodman as vice president of bioanalytical services in its Lincoln, Nebraska, laboratory.Post this
LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, a leading clinical research organization, specializing in early clinical research and bioanalytical services, today announced the appointment of Jo Goodman as vice president of bioanalytical services in its Lincoln, Nebraska, laboratory. In her new role, Goodman will oversee the strategic direction and operational performance of the Lincoln bioanalytical laboratory, leveraging her extensive experience in pharmaceutical research and development to drive innovation and design and execute customized bioanalysis for clients’ needs. She will be responsible for delivering on Celerion’s bioanalytical promise of industry-leading science, stringent compliance, and speed of delivery. With over 29 years of experience in the pharmaceutical industry, Goodman brings a wealth of knowledge in regulated GxP and discovery bioanalysis for both in-house and outsourced activities. Prior to joining Celerion, she held positions of increasing responsibility at AstraZeneca, MedImmune, and GlaxoSmithKline. Additionally, Goodman is a recognized thought leader, having recently served as a member of the Expert Working Group (EWG) for ICH M10 Bioanalytical Guidance Development and is active in numerous non-profit industry consortia such as EBF, AAPS, and DMDG